AR097584A1 - Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano - Google Patents
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humanoInfo
- Publication number
- AR097584A1 AR097584A1 ARP140103345A ARP140103345A AR097584A1 AR 097584 A1 AR097584 A1 AR 097584A1 AR P140103345 A ARP140103345 A AR P140103345A AR P140103345 A ARP140103345 A AR P140103345A AR 097584 A1 AR097584 A1 AR 097584A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- chain variable
- variable domain
- heavy chain
- light chain
- Prior art date
Links
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 102000008096 B7-H1 Antigen Human genes 0.000 title 1
- 108010074708 B7-H1 Antigen Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 2
- 206010038389 Renal cancer Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102000048776 human CD274 Human genes 0.000 abstract 2
- 201000010982 kidney cancer Diseases 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010027406 Mesothelioma Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000010749 gastric carcinoma Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
Reivindicación 1: Un anticuerpo, que se une al CSF-1R humano, donde dicho anticuerpo se administra en combinación con un anticuerpo, que se une al PD-L1 humano, para uso en el tratamiento del cáncer, para uso en la prevención o el tratamiento de metástasis, para uso en el tratamiento enfermedades inflamatorias, para uso en el tratamiento de pérdidas óseas, para uso en el tratamiento o retardo del progreso de una enfermedad de carácter inmune, por ejemplo la inmunidad tumoral o para uso en la estimulación de una respuesta o función inmune, por ejemplo la actividad de las células T, dicho el anticuerpo, que se une al CSF-1R humano, empleado en la terapia de combinación se caracteriza porque contiene a) un dominio variable de cadena pesada VH de SEQ ID Nº 23 y un dominio variable de cadena ligera VL de SEQ ID Nº 24 o b) un dominio variable de cadena pesada VH de SEQ ID Nº 31 y un dominio variable de cadena ligera VL de SEQ ID Nº 32 o c) un dominio variable de cadena pesada VH de SEQ ID Nº 39 y un dominio variable de cadena ligera VL de SEQ ID Nº 40 o d) un dominio variable de cadena pesada VH de SEQ ID Nº 47 y un dominio variable de cadena ligera VL de SEQ ID Nº 48 o e) un dominio variable de cadena pesada VH de SEQ ID Nº 55 y un dominio variable de cadena ligera VL de SEQ ID Nº 56; y el anticuerpo, que se une al PD-L1 humano empleado en la terapia de combinación se caracteriza porque contiene a) un dominio variable de cadena pesada VH de SEQ ID Nº 89 y un dominio variable de cadena ligera VL de SEQ ID Nº 92 o b) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 93 o c) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 94 o d) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 95 o e) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 96 o f) un dominio variable de cadena larga VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 97 o g) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 98 o h) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 99 o i) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 100 o j) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 101 o k) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 102 o l) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 103 o m) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 104 o n) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 105 u o) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 106 o p) un dominio variable de cadena pesada VH de SEQ ID Nº 91 y un dominio variable de cadena ligera VL de SEQ ID Nº 107. Reivindicación 3: El anticuerpo según la reivindicación 2, para uso en el tratamiento del cáncer de mama, el cáncer de pulmón, el cáncer de colon, el cáncer de ovarios, el cáncer de tipo melanoma, el cáncer de vejiga, el cáncer renal, el cáncer de riñón, el cáncer de hígado, el cáncer de cabeza y cuello, el cáncer colorrectal, el cáncer de páncreas, el carcinoma gástrico, el cáncer de esófago, el mesotelioma, el cáncer de próstata, la leucemia, los linfomas, los mielomas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13184120 | 2013-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097584A1 true AR097584A1 (es) | 2016-03-23 |
Family
ID=49123797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103345A AR097584A1 (es) | 2013-09-12 | 2014-09-08 | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20150073129A1 (es) |
| EP (1) | EP3044235B1 (es) |
| JP (2) | JP6526681B2 (es) |
| KR (1) | KR20160035090A (es) |
| CN (2) | CN105473617A (es) |
| AR (1) | AR097584A1 (es) |
| AU (1) | AU2014320355A1 (es) |
| BR (1) | BR112016000903A2 (es) |
| CA (1) | CA2916826A1 (es) |
| HK (1) | HK1217021A1 (es) |
| IL (1) | IL243348A0 (es) |
| MX (1) | MX2016003129A (es) |
| RU (1) | RU2016113757A (es) |
| SG (1) | SG11201601881RA (es) |
| TW (1) | TWI617579B (es) |
| WO (1) | WO2015036511A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE044179T2 (hu) | 2009-12-10 | 2019-10-28 | Hoffmann La Roche | Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| KR20240017102A (ko) * | 2013-12-17 | 2024-02-06 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| JP6877339B2 (ja) | 2014-10-14 | 2021-05-26 | ノバルティス アーゲー | Ｐｄ−ｌ１に対する抗体分子およびその使用 |
| EA036261B1 (ru) | 2014-10-29 | 2020-10-20 | Файв Прайм Терапьютикс, Инк. | Комбинированное лечение злокачественного новообразования |
| US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| PT3283527T (pt) | 2015-04-13 | 2021-03-03 | Five Prime Therapeutics Inc | Terapêutica de combinação para o cancro |
| US10869924B2 (en) * | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| IL256080B2 (en) | 2015-06-17 | 2025-06-01 | Genentech Inc | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| RU2018102575A (ru) * | 2015-06-24 | 2019-07-25 | Ф. Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r, предназначенные для применения для индукции лимфоцитоза при лимфомах или лейкозах |
| EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| TN2017000554A1 (en) | 2015-07-29 | 2019-04-12 | Novartis Ag | Novel combination for use in the treatment of cancer |
| WO2017040790A1 (en) * | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| CN107614529B (zh) | 2015-11-17 | 2019-11-12 | 苏州盛迪亚生物医药有限公司 | Pd-l1抗体、其抗原结合片段及其医药用途 |
| JP2018531278A (ja) * | 2015-11-24 | 2018-10-25 | イーライ リリー アンド カンパニー | 癌のための併用療法 |
| EP3400246B1 (en) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| SG11201810509PA (en) | 2016-06-20 | 2018-12-28 | Kymab Ltd | Anti-pd-l1 antibodies |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| EP3558360A1 (en) * | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| WO2018144334A1 (en) * | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| JP2020512382A (ja) * | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体 |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| MX2019012793A (es) * | 2017-04-27 | 2020-02-13 | Tesaro Inc | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| JP2020535119A (ja) | 2017-09-13 | 2020-12-03 | ファイヴ プライム セラピューティクス インク | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法 |
| WO2019113464A1 (en) * | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| MX2020007406A (es) | 2018-01-10 | 2020-09-14 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. |
| US20210145983A1 (en) * | 2018-04-19 | 2021-05-20 | The Board Of Trustees Of The University Of Illinois | Methods and compositions of inhibiting csf1r for treating allergic inflammation |
| CN110563842B (zh) * | 2018-06-06 | 2022-07-29 | 浙江博锐生物制药有限公司 | 针对程序性死亡配体(pd-l1)的抗体及其应用 |
| HUE073437T2 (hu) | 2018-12-28 | 2026-01-28 | Deciphera Pharmaceuticals Llc | CSF1R gátlók tenoszinoviális óriássejtes tumorok kezelésében való alkalmazásra |
| TWI883241B (zh) * | 2020-08-07 | 2025-05-11 | 大陸商百奧泰生物製藥股份有限公司 | 抗pd-l1抗體及其應用 |
| CN114225023B (zh) * | 2021-12-22 | 2022-10-18 | 宝船生物医药科技(上海)有限公司 | 抗csf-1r抗体联合抗pd-l1抗体的应用 |
| CN114380913B (zh) * | 2022-03-24 | 2022-06-21 | 上海济煜医药科技有限公司 | 一种全人源抗pd-l1抗体及其应用 |
| TW202542127A (zh) | 2023-12-08 | 2025-11-01 | 美商迪賽孚爾製藥有限公司 | 激酶抑制劑之固態形式 |
| US20250205161A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| WO1993025687A1 (en) | 1992-06-09 | 1993-12-23 | Chiron Corporation | Crystallization of m-csf |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| US5571751A (en) | 1994-05-09 | 1996-11-05 | National Semiconductor Corporation | Interconnect structures for integrated circuits |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| EP0977991A4 (en) | 1997-03-03 | 2004-12-15 | Bristol Myers Squibb Co | MONOCLONAL ANTIBODIES FOR HUMAN CD6 |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| CA2304354A1 (en) | 1997-10-02 | 1999-04-15 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
| EP1223980B1 (de) | 1999-10-28 | 2003-05-21 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
| DK1242438T3 (da) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| AU2003291002A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
| AU2005267062C1 (en) | 2004-07-22 | 2013-01-17 | Five Prime Therapeutics, Inc. | Compositions and methods of use for MGD-CSF in disease treatment |
| AR054428A1 (es) | 2005-03-08 | 2007-06-27 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina |
| EP1885399B1 (en) | 2005-05-26 | 2010-10-20 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| WO2007075326A2 (en) | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using cd40 binding agents |
| EP1984024A2 (en) | 2006-01-05 | 2008-10-29 | Novartis AG | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| US20070280935A1 (en) | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| EP2079305A4 (en) | 2006-12-12 | 2010-01-27 | Idera Pharmaceuticals Inc | SYNTHETIC AGONISTS OF TLR9 |
| AU2007339897B2 (en) | 2006-12-27 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of infections and tumors |
| CN101636412A (zh) | 2007-03-30 | 2010-01-27 | 霍夫曼-拉罗奇有限公司 | 标记的和非标记的单克隆抗体的组合物 |
| AU2008262384B9 (en) | 2007-06-05 | 2014-11-27 | Yale University | Inhibitors of receptor tyrosine kinases and methods of use thereof |
| EP3330292A1 (en) | 2007-08-21 | 2018-06-06 | Amgen, Inc | Human c-fms antigen binding proteins |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| EP2262836B1 (en) | 2008-03-14 | 2016-03-09 | Transgene SA | Antibody against the csf-1 r |
| CN102046660A (zh) | 2008-03-26 | 2011-05-04 | 塞勒兰特治疗公司 | 骨髓性血液学增殖性病症相关的免疫球蛋白和/或toll样受体蛋白及其用途 |
| EP4331604B9 (en) | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| AU2010208250A1 (en) | 2009-01-30 | 2011-08-04 | Idera Pharmaceuticals, Inc. | Synthetic agonists of TLR 9 |
| HUE028537T2 (en) | 2009-04-20 | 2016-12-28 | Kyowa Hakko Kirin Co Ltd | Built-in amino acid mutation IgG2 antibody |
| CA2778714C (en) * | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
| HUE044179T2 (hu) | 2009-12-10 | 2019-10-28 | Hoffmann La Roche | Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása |
| EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| NZ603193A (en) | 2010-05-04 | 2014-07-25 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
| JP5798404B2 (ja) | 2010-08-31 | 2015-10-21 | 日東電工株式会社 | 極板保護用粘着テープ |
| WO2012068470A2 (en) | 2010-11-19 | 2012-05-24 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
| KR101614195B1 (ko) | 2011-03-29 | 2016-04-20 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| JP2014520873A (ja) | 2011-07-18 | 2014-08-25 | ザ ユニバーシティ オブ メルボルン | ｃ−Ｆｍｓアンタゴニストの使用 |
| KR20190133790A (ko) | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| HK1200032A1 (en) | 2011-10-21 | 2015-07-31 | Transgene Sa | Modulation of macrophage activation |
| ES2808152T3 (es) * | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| HK1212214A1 (en) | 2012-08-31 | 2016-06-10 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| SG11201502827RA (en) | 2012-11-09 | 2015-05-28 | Transgene Sa | Modulation of monocytes, or precursors thereof, differentiation |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP2963764A1 (en) | 2014-07-02 | 2016-01-06 | Delphi Technologies, Inc. | Apparatus to provide reverse polarity protection |
| EP3180087B1 (en) | 2014-08-12 | 2019-03-13 | Alligator Bioscience AB | Combination therapies with anti cd40 antibodies |
| EA036261B1 (ru) | 2014-10-29 | 2020-10-20 | Файв Прайм Терапьютикс, Инк. | Комбинированное лечение злокачественного новообразования |
| SG11201703605QA (en) | 2014-11-17 | 2017-06-29 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| EP3240801B1 (en) | 2014-12-31 | 2021-01-20 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
| CN107847481A (zh) | 2015-06-03 | 2018-03-27 | 波士顿生物医药有限公司 | 包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂 |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| EP3589324A1 (en) | 2017-03-03 | 2020-01-08 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| US11078283B2 (en) | 2018-01-17 | 2021-08-03 | Apexigen, Inc. | Anti-PD-L1 antibodies and methods of use |
| KR20210062027A (ko) | 2018-09-13 | 2021-05-28 | 에프. 호프만-라 로슈 아게 | Csf-1r 항체 제제 |
-
2014
- 2014-09-08 AR ARP140103345A patent/AR097584A1/es unknown
- 2014-09-11 TW TW103131444A patent/TWI617579B/zh not_active IP Right Cessation
- 2014-09-11 JP JP2016542318A patent/JP6526681B2/ja active Active
- 2014-09-11 WO PCT/EP2014/069451 patent/WO2015036511A1/en not_active Ceased
- 2014-09-11 CN CN201480045288.2A patent/CN105473617A/zh not_active Withdrawn
- 2014-09-11 MX MX2016003129A patent/MX2016003129A/es unknown
- 2014-09-11 CN CN202411475373.4A patent/CN119303076A/zh active Pending
- 2014-09-11 HK HK16105004.5A patent/HK1217021A1/zh unknown
- 2014-09-11 AU AU2014320355A patent/AU2014320355A1/en not_active Abandoned
- 2014-09-11 CA CA2916826A patent/CA2916826A1/en not_active Abandoned
- 2014-09-11 SG SG11201601881RA patent/SG11201601881RA/en unknown
- 2014-09-11 EP EP14761904.3A patent/EP3044235B1/en active Active
- 2014-09-11 KR KR1020167006340A patent/KR20160035090A/ko not_active Ceased
- 2014-09-11 BR BR112016000903A patent/BR112016000903A2/pt not_active IP Right Cessation
- 2014-09-11 RU RU2016113757A patent/RU2016113757A/ru not_active Application Discontinuation
- 2014-09-12 US US14/485,140 patent/US20150073129A1/en not_active Abandoned
-
2015
- 2015-12-24 IL IL243348A patent/IL243348A0/en unknown
-
2016
- 2016-07-29 US US15/223,897 patent/US20170051065A1/en not_active Abandoned
-
2018
- 2018-04-19 US US15/957,387 patent/US20180346581A1/en not_active Abandoned
- 2018-07-23 JP JP2018137794A patent/JP2019001789A/ja active Pending
-
2020
- 2020-02-06 US US16/784,203 patent/US11512133B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201522376A (zh) | 2015-06-16 |
| EP3044235A1 (en) | 2016-07-20 |
| AU2014320355A1 (en) | 2016-02-18 |
| BR112016000903A2 (pt) | 2017-12-12 |
| JP6526681B2 (ja) | 2019-06-05 |
| JP2019001789A (ja) | 2019-01-10 |
| US20180346581A1 (en) | 2018-12-06 |
| KR20160035090A (ko) | 2016-03-30 |
| CN119303076A (zh) | 2025-01-14 |
| EP3044235B1 (en) | 2020-09-02 |
| JP2016531150A (ja) | 2016-10-06 |
| US20200392234A1 (en) | 2020-12-17 |
| SG11201601881RA (en) | 2016-04-28 |
| US11512133B2 (en) | 2022-11-29 |
| CA2916826A1 (en) | 2015-03-19 |
| TWI617579B (zh) | 2018-03-11 |
| US20150073129A1 (en) | 2015-03-12 |
| US20170051065A1 (en) | 2017-02-23 |
| IL243348A0 (en) | 2016-03-31 |
| MX2016003129A (es) | 2016-08-08 |
| WO2015036511A1 (en) | 2015-03-19 |
| CN105473617A (zh) | 2016-04-06 |
| HK1217021A1 (zh) | 2016-12-16 |
| RU2016113757A (ru) | 2017-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097584A1 (es) | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano | |
| PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
| PH12017501728A1 (en) | Chimeric antigen receptors targeting b-cell maturation antigen | |
| PH12019502637A1 (en) | Chimeric antigen receptors targeting flt3 | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
| UY36862A (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения | |
| ECSP17021097A (es) | Compuestos de aminopiridiloxipirazol | |
| MX2017013801A (es) | Métodos para tratar el cáncer. | |
| HK1250918A1 (zh) | 用於胶质母细胞瘤的egfr导向的car疗法 | |
| MX2021003704A (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales. | |
| PE20181066A1 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
| EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
| CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
| MX377844B (es) | Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso. | |
| EA201790799A1 (ru) | Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей | |
| PE20171060A1 (es) | Receptores quimericos de antigeno anti-cldn y metodos de uso | |
| PE20171383A1 (es) | Receptores de antigeno quimericos anti-dll3 y metodos de uso | |
| CY1123593T1 (el) | Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου | |
| MX383966B (es) | Composiciones y métodos mejorados para la entrega viral de neoepítopos y usos de estos. | |
| MX2024003627A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso. | |
| MX2019009724A (es) | Nueva estrategia de inmunoterapia dirigida al vegfr-2. | |
| CL2016002891A1 (es) | Compuestos de vegfr2/ang2 | |
| EA201991027A9 (ru) | АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |